Cover Image
市場調查報告書

醫療影像用試劑市場:各級,技術,用途 - 全球機會分析及產業預測

Medical Imaging Reagents Market by Class (Contrast Reagents, Optical Reagents, and Nuclear Reagents), Technology, and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 563252
出版日期 內容資訊 英文 160 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫療影像用試劑市場:各級,技術,用途 - 全球機會分析及產業預測 Medical Imaging Reagents Market by Class (Contrast Reagents, Optical Reagents, and Nuclear Reagents), Technology, and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年09月01日 內容資訊: 英文 160 Pages
簡介

本報告提供全球醫療影像用試劑市場相關調查,彙整市場各級,各技術,各用途,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 法律規章與給付方案
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各類型市場

  • 概要
  • 顯影劑
  • 光學試劑
  • 核醫學用試劑

第5章 各技術市場

  • 概要
  • 奈米粒子
  • 螢光染料·探針
  • 放射性醫藥品
  • 螢光蛋白質
  • 量子點

第6章 各用途市場

  • 概要
  • 診斷
  • 藥物研發·開發
  • 研究開發

第7章 各地區市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第8章 企業簡介

目錄
Product Code: LI 171664

Medical imaging reagents are chemicals used in imaging and detection technologies to visualize organs or structures. These reagents enable physicians to diagnose and detect diseases, thus playing a vital role in the healthcare and medical industry. The modern approach involves using these reagents in animal research before their reaction can be evaluated on humans. These reagents have addressed the increasing need for better therapeutics as they assist in detecting changes at the molecular level with the aid of X-ray and ultrasound. The global medical imaging reagents market was valued at $10,772 million in 2016, and is estimated to reach $18,587 million by 2023, registering a CAGR of 8.0% from 2017 to 2023.

The global medical imaging reagents market is driven by rise in cases of chronic diseases such as cancer and cardiovascular diseases, increase in technological advancements, and high unmet medical and diagnostic imaging procedure needs. In addition, rise in geriatric population, increase in expenditure on healthcare, and growth in demand for effective procedures and safe medication are expected to fuel the market growth. However, lack of reagent suppliers and strict government regulations restrict this growth in developing regions.

The global medical imaging reagents market is segmented based on class, technology, application, and geography. Based on class, it is divided into contrast reagents, optical reagents, and nuclear reagents. The technology segment includes nanoparticles, fluorescent dyes & probes, radiopharmaceuticals, fluorescent proteins, and quantum dots. Based on application, the market is categorized into diagnostics, drug discovery & development, and R&D. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS:

  • This report offers a detailed quantitative analysis of the current market trends of the global medical imaging reagents market from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive market scenario.

KEY PLAYERS PROFILED:

  • Bracco Imaging SpA
  • Bayer Healthcare AG
  • Lantheus Medical Imaging, Inc.
  • GE Healthcare
  • Siemens Healthcare
  • Covalon Technologies Ltd.
  • Thermo Fisher Scientific, Inc.
  • Merck
  • Philips Healthcare
  • Shimadzu Corporation

KEY MARKET SEGMENTS:

By Class

  • Contrast Reagents
  • Optical Reagents
  • Nuclear Reagents

By Technology

  • Nanoparticles
  • Fluorescent Dyes & Probes
  • Radiopharmaceuticals
  • Fluorescent Proteins
  • Quantum Dots

By Application

  • Diagnostics
  • Drug Discovery & Development
  • R&D

By Geography

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Republic of South Africa
  • Saudi Arabia
  • Rest of LAMEA

The other players of the dialysis market include (companies not profiled in the report):

  • Guerbet Group
  • Daiichi Sankyo
  • nanoPET Pharma GmbH
  • Subhra Pharma Private Limited
  • CMC Contrast AB

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. REGULATION AND REIMBURSEMENT SCENARIO
  • 3.5. MARKET DYNAMICS
    • 3.5.1. Drivers
      • 3.5.1.1. Growth in number of geriatric population
      • 3.5.1.2. Increase in prevalence of chronic diseases
      • 3.5.1.3. Rise in demand for diagnostic imaging procedures
    • 3.5.2. Restraints
      • 3.5.2.1. Shortage of supplies of imaging reagents
      • 3.5.2.2. Stringent regulatory approvals
      • 3.5.2.3. Reluctance in adopting nuclear reagents
    • 3.5.3. Opportunities
      • 3.5.3.1. Technological Advancements Leading
      • 3.5.3.2. Development of personalized therapy
      • 3.5.3.3. Untapped Markets in Developing Economies

CHAPTER 4 MEDICAL IMAGING REAGENTS MARKET, BY TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. CONTRAST REAGENTS
    • 4.2.1. Market size and forecast
  • 4.3. OPTICAL REAGENTS
    • 4.3.1. Market size and forecast
  • 4.4. NUCLEAR REAGENTS
    • 4.4.1. Market size and forecast

CHAPTER 5 MEDICAL IMAGING REAGENTS MARKET, BY TECHNOLOGY

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. NANOPARTICLES
    • 5.2.1. Market size and forecast
  • 5.3. FLUORESCENT DYES & PROBES
    • 5.3.1. Market size and forecast
  • 5.4. RADIOPHARMACEUTICALS
    • 5.4.1. Market size and forecast
  • 5.5. FLUORESCENT PROTEINS
    • 5.5.1. Market size and forecast
  • 5.6. QUANTUM DOTS
    • 5.6.1. Market size and forecast

CHAPTER 6 MEDICAL IMAGING REAGENTS MARKET, BY APPLICATIONS

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. DIAGNOSTICS
    • 6.2.1. Market size and forecast
  • 6.3. DRUG DISCOVERY & DEVELOPMENT
    • 6.3.1. Market size and forecast
  • 6.4. R&D
    • 6.4.1. Market size and forecast

CHAPTER 7 MEDICAL IMAGING REAGENTS MARKET, BY GEOGRAPHY

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. NORTH AMERICA
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast
      • 7.2.3.1. U.S. market size and forecast
      • 7.2.3.2. Mexico market size and forecast
      • 7.2.3.3. Canada market size and forecast
  • 7.3. EUROPE
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast
      • 7.3.3.1. UK market size and forecast
      • 7.3.3.2. France market size and forecast
      • 7.3.3.3. Germany market size and forecast
      • 7.3.3.4. Rest of Europe market size and forecast
  • 7.4. ASIA-PACIFIC
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast
      • 7.4.3.1. India market size and forecast
      • 7.4.3.2. Japan market size and forecast
      • 7.4.3.3. China market size and forecast
      • 7.4.3.4. Rest of Asia-Pacific market size and forecast
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. Market size and forecast
      • 7.5.3.1. Brazil market size and forecast
      • 7.5.3.2. South Africa market size and forecast
      • 7.5.3.3. Saudi Arabia market size and forecast
      • 7.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

  • 8.1. BRACCO IMAGING SPA
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Business performance
    • 8.1.5. Key strategic moves and developments
  • 8.2. BAYER HEALTHCARE AG
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Business performance
    • 8.2.5. Key strategic moves and developments
  • 8.3. LANTHEUS MEDICAL IMAGING, INC.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. GE HEALTHCARE
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. SIEMENS HEALTHCARE
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
    • 8.5.5. Key strategic moves and developments
  • 8.6. MALLINCKRODT PHARMACEUTICALS
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
    • 8.6.5. Key strategic moves and developments
  • 8.7. THERMO FISHER SCIENTIFIC, INC.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
    • 8.7.5. Key strategic moves and developments
  • 8.8. MERCK
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
    • 8.8.5. Key strategic moves and developments
  • 8.9. BECTON DICKINSON & COMPANY
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
    • 8.9.5. Key strategic moves and developments
  • 8.10. CARDINAL HEALTH, INC.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Business performance
    • 8.10.5. Key strategic moves and developments
Back to Top